Extended clinical sample incubation in the cepheid Xpert MTB/XDR test sample reagent: Enhancing flexibility and workflows in high-volume laboratories.

Diagnostic GeneXpert Mycobacterium tuberculosis

Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
24 Aug 2024
Historique:
received: 06 05 2024
revised: 17 08 2024
accepted: 21 08 2024
medline: 1 9 2024
pubmed: 1 9 2024
entrez: 31 8 2024
Statut: aheadofprint

Résumé

Cepheid Xpert MTB/RIF ULTRA (ULTRA) and Xpert MTB/XDR are tests for detecting Mycobacterium tuberculosis (MTB) and drug resistance. Both tests involve a sample pre-processing step using the test's sample reagent (SR). The manufacturer recommends a four-hour limit for SR-treated samples prior to testing, posing challenges for high-volume laboratories conducting both tests. Implementing the XDR test as a follow-on to ULTRA positive specimen can be challenging in high-volume laboratories due to the time constraints imposed by the manufacturer's recommendations. To address this issue, this study investigated the impact of extended sample incubation in SR for durations longer than four hours at varying temperature conditions. Pre-characterized MTB isolates with diverse drug susceptibility profiles were incubated up to 36 hours at different temperatures including room temperature (RT), 2-8°C, and -20°C and tested using Xpert MTB/XDR. The study results indicate no adverse effects on sample stability or drug susceptibility detection. This suggests extended incubation could offer flexibility for conducting both tests on a single specimen, benefiting high-throughput laboratories.

Identifiants

pubmed: 39216193
pii: S0732-8893(24)00330-4
doi: 10.1016/j.diagmicrobio.2024.116504
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116504

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Auteurs

Yamkela Qumbelo (Y)

Centre for Tuberculosis, National Institute for Communicable diseases, National Health Laboratory Services, 1 Modderfontein Road, Sandringham, Gauteng, South Africa, 2192.

Elizabeth Kachingwe (E)

Centre for Tuberculosis, National Institute for Communicable diseases, National Health Laboratory Services, 1 Modderfontein Road, Sandringham, Gauteng, South Africa, 2192.

Shaheed Vally Omar (SV)

Centre for Tuberculosis, National Institute for Communicable diseases, National Health Laboratory Services, 1 Modderfontein Road, Sandringham, Gauteng, South Africa, 2192; Department of Medical Microbiology, University of Pretoria, Prinshof, Pretoria, Gauteng, South Africa, 0084; Department of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand Medical School, 7 York Street, Parktown, Gauteng, South Africa, 2193. Electronic address: shaheedvo@nicd.ac.za.

Classifications MeSH